Serum Bicarbonate: Reconsidering the Importance of a Neglected Biomarker in Predicting Clinical Outcomes in Sepsis

Robin Paudel 1, Brittany Bissell 2, Prerna Dogra 3, Peter E. Morris 4, Said Chaaban 4

1. Pulmonary and Critical Care Medicine, Mayo Clinic Health System, La Crosse, USA
2. Pharmacy Practice and Science, University of Kentucky, Lexington, USA
3. Endocrinology (Diabetes and Metabolism), Mayo Clinic, Rochester, USA
4. Pulmonary, Critical Care, and Sleep Medicine/Internal Medicine, University of Kentucky College of Medicine, Lexington, USA

Corresponding author: Robin Paudel, paudel.robin@mayo.edu

Abstract

Background

Despite being an important pathophysiological component, information on the predictive value of serum bicarbonate level in sepsis is limited.

Study design and method

This is a single-centered retrospective study involving 4176 patients admitted to the medical ICU (MICU) with a diagnosis of sepsis. Patients were divided into two groups based on the presence or absence of chronic kidney disease (CKD) on admission: CKD and non-CKD, respectively. Each group was then divided into three sub-groups based on serum bicarbonate level at presentation (in mEq/l) - low (<22), normal (22-28), and high (>28). We compared the clinical outcomes between the sub-groups in each group, with in-hospital mortality as the primary endpoint. Secondary endpoints included vasopressor-free days, ventilator-free days, ICU-free days, and hospital-free days.

Result

In both the CKD and non-CKD groups, low serum bicarbonate was associated with significantly increased in-hospital mortality. There was no difference in the mortality between the sub-groups with normal and high serum bicarbonate. When adjusted for other known predictors of mortality, the association of low serum bicarbonate with increased in-hospital mortality was statistically significant only in the patient group with a Sequential Organ Failure Assessment (SOFA) score of ≥9. Additionally, the SOFA score had a better predictive value for in-hospital mortality, ICU-free days, and ventilator-free days when the serum bicarbonate level was <22.

Interpretation

Serum bicarbonate is a good predictor of clinical outcomes in sepsis and can be used along with other markers of sepsis to predict clinical outcomes.

Introduction

Sepsis is a life-threatening syndrome of organ dysfunction caused by infection and dysregulated host response to the infection [1,2]. It is the leading cause of death worldwide, with an estimated incidence of 31.5 million cases of sepsis, 19.4 million cases of severe sepsis, and 5.3 million deaths per year [3]. Markers of sepsis that predict morbidity and mortality, such as Acute Physiology and Chronic Health Evaluation (APACHE) score, Sequential Organ Failure Assessment (SOFA) score, Simplified Acute Physiology Score (SAPS) score, serum lactate level, and mean arterial pressure, have been extensively studied [4-9]. Despite being an important pathophysiological component of sepsis, information on serum bicarbonate level and its predictive value in sepsis are limited. Hemodynamic instability in critically ill patients with sepsis can induce multiple organ compromise, including renal dysfunction and tissue hypoperfusion, both of which are widely believed to cause decreased serum bicarbonate levels. Recent studies have suggested that serum bicarbonate can neither be a surrogate for lactate nor can it accurately predict the lactate level in patients with sepsis [10-12]. To the best of our knowledge, ours is the first large study to look at the relation between serum bicarbonate and clinical outcomes in patients with sepsis. We hypothesize that serum bicarbonate level at presentation is a predictor of morbidity and short-term mortality in patients with sepsis admitted to the medical intensive care unit (MICU).
Materials And Methods

After approval by the University of Kentucky Institutional Review Board (approval number 47751), we performed a single-center retrospective research study on patients admitted to the MICU of the University of Kentucky Medical Center, Lexington, Kentucky, United States, with a diagnosis of sepsis, severe sepsis, and septic shock from January 2012 to December 2017. We used International Classification of Diseases (ICD) 9 and 10 codes to identify these patients. The exclusion criteria were age < 18 years, end-stage renal disease requiring dialysis, or missing serum bicarbonate level at presentation defined as within four hours of admission to MICU. A total of 5293 patients met the inclusion criteria, of which 1117 patients were excluded. The final cohort consisted of 4176 subjects. The primary outcome was in-hospital mortality, defined as death before hospital discharge. Secondary outcomes included hospital-free days, ICU-free days, ventilator-free days, and pressor-free days, all calculated at 28 days. Patients with a diagnosis of severe sepsis were included in the study because we also used ICD 9 for the identification of patients.

Stata Statistical Software: Release 13, 2013 (StataCorp LP, College Station, Texas, United States) was used for statistical analysis. We first evaluated the unadjusted predictive value of serum bicarbonate in sepsis. Then, we adjusted the outcomes for co-morbidities and other known predictors of clinical outcomes in sepsis.

For the unadjusted predictive value of serum bicarbonate, the study cohort was first divided into three groups based on serum bicarbonate level at presentation: serum bicarbonate level <22, serum bicarbonate level 22-28, and serum bicarbonate level >28. In-hospital mortality was then compared among these groups. The study cohort was then divided into two major groups based on the presence or absence of chronic kidney disease (CKD) on admission: CKD and non-CKD groups, respectively. Each group was then divided into three subgroups based on serum bicarbonate at presentation: low bicarbonate (<22 mEq/L), normal bicarbonate (22-28 mEq/L), and high bicarbonate (>28 mEq/L). The mortality in the three sub-groups within each group was then compared using a Chi-square test.

To calculate the adjusted predictive value of serum bicarbonate, the study cohort was divided into three groups: group 1 (bicarbonate level <22 mEq/L), group 2 (bicarbonate level 22-28 mEq/L), and group 3 (bicarbonate level >28 mEq/L). The clinical outcomes in groups 1 and 3 were then compared to those in group 2. We used a multiple regression model adjusted for age, gender, SOFA score, and co-morbidities (CKD, chronic obstructive pulmonary disease (COPD), liver cirrhosis). Based on the distribution shown in plots (Figure 1 and Figure 2), we conducted Zero-Inflated Poisson regression models to look at the hospital-free days and ICU-free days as clinical outcomes.
Based on the distribution shown in plots (Figure 2 and Figure 3), we first transformed the outcome variables by dividing the ventilator-free days and pressor-free days by 28. We then conducted Zero-One Inflated Beta regression models to look at the impacts of bicarbonate on these clinical outcomes.

**FIGURE 2: ICU-free days distribution plot**

**FIGURE 3: Ventilator-free days distribution plot**
Results

Patient characteristics are given in Table 1.

| Bicarbonate on MICU Admission | CKD Dx | No CKD Dx | P-value | n | CKD Dx | No CKD Dx | P-value | n |
|-------------------------------|--------|-----------|---------|---|--------|-----------|---------|---|
| Number of Patient Visits      | < 22   | 22 to 28  | > 28    |   | < 22   | 22 to 28  | > 28    |   |
| Average Age                   | 61.911 | 64.053    | 64.932  | 0.010 | 835    | 53.925    | 54.936  | 57.311 | < 0.001 | 3341 |
| Average BMI                   | 31.981 | 33.578    | 34.951  | 0.111 | 808    | 29.082    | 29.395  | 32.217 | < 0.032 | 3184 |
| Percentage Male               | 54.95% | 56.50%    | 60.81%  | 0.622 | 835    | 48.59%    | 52.67%  | 54.01% | < 0.030 | 3341 |
| Percentage White              | 91.46% | 93.09%    | 91.89%  | 0.270 | 835    | 93.85%    | 94.22%  | 95.69% | < 0.028 | 3341 |
| Average SOFA Score            | 10.548 | 8.955     | 7.966   | < 0.001 | 835    | 10.291    | 7.892  | 7.100  | < 0.001 | 3341 |
| Average Heart Rate            | 97.480 | 90.069    | 86.919  | < 0.001 | 835    | 105.370   | 102.713 | 98.638 | < 0.001 | 3340 |
| Average Mean Blood Pressure   | 72.707 | 77.715    | 79.230  | < 0.001 | 835    | 73.249    | 79.617  | 81.804 | < 0.001 | 3340 |
| Average Temperature           | 97.847 | 98.516    | 98.176  | < 0.001 | 834    | 98.041    | 98.762  | 98.694 | < 0.001 | 3338 |
| Average Respiratory Rate      | 21.130 | 20.919    | 19.581  | 0.053  | 835    | 22.724    | 21.449  | 20.875 | < 0.001 | 3339 |
| Average Bicarbonate Minimum   | 13.460 | 20.187    | 25.041  | < 0.001 | 835    | 13.771    | 20.924  | 27.174 | < 0.001 | 3341 |
| Average Bicarbonate at 48 Hours| 18.585 | 23.296    | 30.554  | < 0.001 | 642    | 19.126    | 24.547  | 31.991 | < 0.001 | 2475 |
| Average Lactate               | 3.350  | 1.772     | 1.735   | < 0.001 | 796    | 4.509     | 2.317  | 1.742  | < 0.001 | 3173 |
### TABLE 1: Unadjusted for other known predictors of clinical outcomes in sepsis

CKD: Chronic Kidney Disease; MICU: Medical Intensive Care Unit; BMI: Body Mass Index; SOFA: Sequential Organ Failure Assessment, eGFR: Estimated Glomerular Filtration Rate, LTACH: Long Term Acute Care Hospital, Dx: Diagnosis

In the final cohort of 4176 patients, irrespective of the presence or absence of CKD (Table 2), in-hospital mortality was significantly higher in the patients with low serum bicarbonate compared to normal or high serum bicarbonate (p-value<0.0001). Additionally, noted in the low bicarbonate subgroup of both the CKD and non-CKD groups were significantly high SOFA score, low mean arterial pressure, low temperature, low pH, low albumin, high lactate, low estimated glomerular filtration rate (eGFR), and high anion gap. (Table 1).
Bicarbonate on MICU admission

| Bicarbonate on MICU admission | <22 | 22-28 | >28 | p-value |
|------------------------------|-----|-------|-----|---------|
| Number of patient visits (n) | 2221| 1370  | 585 |         |
| In-Hospital mortality        | 41.78%| 29.27%| 29.23%| <0.001 |

Mortality in group with bicarbonate <22 compared to group with bicarbonate 22-28, chi²=56.9093 (p-value <0.0001)

Mortality in group with bicarbonate <22 compared to group with bicarbonate >28, chi²=30.6197 (p-value <0.0001)

Mortality in group with bicarbonate 22-28 compared to group with bicarbonate >28, chi²=0.0003 (p-value=0.986)

### TABLE 2: Mortality comparison among different bicarbonate groups

|                | Patients with history of CKD | Patients with no history of CKD |
|----------------|------------------------------|---------------------------------|
|                | Chi-square       | p-value | Chi-square       | p-value |
| Bicarbonate <22 vs 22-28 | 6.125           | 0.013   | 51.971           | <0.001  |
| Bicarbonate <22 vs >28   | 0.986           | 0.321   | 31.459           | <0.001  |
| Bicarbonate 22-28 vs >28 | 0.288           | 0.592   | 0.032            | 0.858   |

When the final cohort was divided into CKD and non-CKD groups (Table 3), the low bicarbonate sub-group had higher in-hospital mortality compared to the normal bicarbonate sub-group in both the CKD (p=0.013) and non-CKD (p=0.001) groups. In comparing the low bicarbonate sub-group to the high bicarbonate sub-group, this difference was statistically significant only in the non-CKD group (p<0.001). For secondary outcomes, in both the CKD and non-CKD groups, more patients with low serum bicarbonate levels required vasopressors and these patients had significantly fewer pressor-free days compared to patients with normal or high bicarbonate levels (p-value<0.001). Regarding other secondary outcomes, only patients in the low bicarbonate sub-group of the non-CKD group had significantly fewer hospital-free days, ICU-free days, and ventilator-free days (p-value<0.001), and no statistically significant difference was seen in the three subgroups with CKD.

### TABLE 3: Mortality comparison among different bicarbonate sub-groups in CKD and non-CKD groups

|                  | Patients with history of CKD | Patients with no history of CKD |
|------------------|------------------------------|---------------------------------|
|                  | Chi-square       | p-value | Chi-square       | p-value |
| Bicarbonate <22 vs 22-28 | 6.125           | 0.013   | 51.971           | <0.001  |
| Bicarbonate <22 vs >28   | 0.986           | 0.321   | 31.459           | <0.001  |
| Bicarbonate 22-28 vs >28 | 0.288           | 0.592   | 0.032            | 0.858   |

Using a multivariate logistic regression model adjusted for age, gender, CKD, COPD, liver cirrhosis, and SOFA score, the primary outcome was compared between group 1 (bicarbonate level <22 mEq/L), group 2 (bicarbonate level 22-28 mEq/L), and group 3 (bicarbonate level >28 mEq/L). As we found a significant interaction between the SOFA score and low bicarbonate, this interaction term was then introduced into the regression model. We found that when adjusted for these variables, the association of low serum bicarbonate with increased in-hospital mortality was seen only when the SOFA score was > 9. When bicarbonate was higher than 28, the mortality rate was higher but not statistically significant (Table 4).
In addition, the interaction term between the low bicarbonate group and the SOFA score was significantly positive, suggesting that the impact of the SOFA score on mortality was higher among patients in group 1. The odds ratio of the SOFA score for the normal bicarbonate group was 1.236 (Table 5), suggesting a 23.6% increase in the odds of mortality for every unit increase in the SOFA score. The odds ratio of SOFA score for the low bicarbonate group was 1.300 (exp (0.212+0.05)) (Table 4), suggesting a 30.0% increase in the odds of mortality for every unit increase in the SOFA score.

The estimation coefficients of the Poisson regression model for hospital-free days are listed in Table 4. The interaction between group 1 and SOFA score was not significant and was not included for further analysis. For the non-zero portion, Group 1 had significantly higher hospital-free days, while group 3 had...
significantly lower hospital-free days. The incident rate ratio for group 1 was 1.059 and that for group 3 was 0.921.

The estimation coefficients of the Poisson regression model for ICU-free days are listed in Table 4. For the non-zero portion, patients in group 3 (bicarbonate > 28) had significantly fewer ICU-free days (p<0.01). The interaction term of bicarbonate group 1 and SOFA score was negative suggesting that the difference in ICU-free days between the low bicarbonate group and the normal bicarbonate group would depend on patients’ SOFA score. When the SOFA score was > 11 (0.141/0.015; Table 4), patients in group 1 had fewer ICU-free days. This also suggested that the impact of SOFA score on the ICU-free days was more significant on patients in group 1 compared to group 2. For group 2, for every unit increase in the SOFA score, there was a 1.8 % decrease in ICU-free days (Table 4). For group 1, for every unit increase in the SOFA score, there was a 3.1 % decrease in ICU-free days.

The estimation coefficients of the Beta regression model portion for ventilator-free days are listed in Table 4. The interaction term of bicarbonate group 1 and SOFA score was negative suggesting that the difference in ventilator-free days between group 1 and group 2 was dependent on the SOFA score, although the difference was not statistically significant (p=0.052). When the SOFA score was ≥ 12 (0.296/0.025; Table 4), patients in group 1 had fewer transformed ventilator-free days suggesting that the impact of SOFA score on the ventilator-free days was larger on patients in group 1 compared to group 2. For patients in group 2, with every unit increase in SOFA score, there was a 4.5 % decrease in the average transformed ventilator-free days. For patients in group 1, with every unit increase in SOFA score, there was a 6.9 % decrease in the average transformed ventilator-free days.

The estimation coefficients of the Beta regression model portion for pressor-free days are listed in Table 4. The interaction between group 1 and SOFA score was not significant and was not included for further analysis. We found that there was no significant difference in pressor-free days between the groups.

**Discussion**

Sepsis and its complications remain the leading cause of morbidity and mortality worldwide [3,13]. Metabolic acidosis [14,15], elevated lactate [16-20], and acute kidney injury [21-23] are known predictors of worse clinical outcomes in patients with sepsis. While these factors have been extensively investigated for their role in sepsis, the predictive value of serum bicarbonate in sepsis remains unexplored. Recent studies have shown that serum bicarbonate and lactate do not correlate, suggesting that serum bicarbonate cannot be a surrogate for lactate and vice versa [10-12, 24]. Moreover, with a significant proportion of hospitals in rural areas operating without access to rapid lactate levels [25,26], knowing the predictive value of serum bicarbonate in sepsis will always help in risk stratification.

In this retrospective analysis including 4176 patients, we investigated the predictive value of serum bicarbonate in sepsis. Our study suggests that serum bicarbonate level at presentation can predict in-hospital mortality as well as the ICU-free days, ventilator-free days, and hospital-free days. In our unadjusted analysis, serum bicarbonate level < 22 mEq/l had a significant association with elevated in-hospital mortality; however, when controlled for confounders, the difference in the in-hospital mortality was not statistically significant except for when the SOFA score was ≥9. When the SOFA score was ≥9, the mortality rate among patients with serum bicarbonate levels < 22meq/l was significantly higher. Similarly, patients with low serum bicarbonate (< 22 mEq/l) had significantly fewer ICU-free days when the SOFA score was ≥11 and significantly fewer ventilator-free days when the SOFA score was ≥12. In contrast, patients with low serum bicarbonate had significantly more hospital-free days while the patients with high serum bicarbonate had fewer hospital-free days compared to patients with normal serum bicarbonate. It was not clear from this study, however, why the patients with low serum bicarbonate had higher hospital-free days.

An interesting finding of our study was the interaction between SOFA score and serum bicarbonate at presentation suggesting that the predictive value of SOFA score for in-hospital mortality, ICU-free days, ventilator-free days, and hospital-free days was higher among patients with low serum bicarbonate. This brings up a valid question if we should incorporate serum bicarbonate levels into the SOFA score to predict clinical outcomes.

Increasing attention has been dedicated to the utilization of sodium bicarbonate in the treatment of sepsis. Current guidelines [13] recommend against its use based on two small cohort studies [27,28]. However, a few recent studies suggested improved mortality with the administration of sodium bicarbonate in a subset of patients with acute kidney injury [29,30] based on which, a weak recommendation was made in favor of sodium bicarbonate therapy in a subset of patients with septic shock, severe metabolic acidosis (pH < 7.2), and acute kidney injury (AKI) (Acute Kidney Injury Network (AKIN) score 2 or 3). Of note, patients in this study were included if their enrollment SOFA score exceeded 4. Based on our study, low serum bicarbonate had a worse clinical outcome only when the SOFA score was ≥9. With these findings, we propose that the clinical outcomes might be better if the patient population is appropriately chosen with a SOFA score of ≥9 for further studies involving the administration of bicarbonate in patients with sepsis.
Given the retrospective nature of our study, multiple limitations exist. The limitations of our study include the fact that (a) it was a single-center study, (b) the study had a retrospective design, and (c) the reason behind the high bicarbonate level (>28 mEq/L) was not investigated.

**Conclusions**

Given the widespread availability of serum bicarbonate levels in health care facilities around the globe, we believe that the utilization of serum bicarbonate levels at presentation along with other markers of sepsis can help in the prognostication of these patients with sepsis. Also noted in our study is the predictive value of the SOFA score was dependent on the serum bicarbonate level at presentation. Based on this result, we believe that incorporating serum bicarbonate level in the SOFA score might increase the predictive value of the SOFA score. We propose that further prospective studies be performed to evaluate the utilization of serum bicarbonate for these purposes.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. University of Kentucky Institutional Review Board issued approval 47751. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Rhodes A, Evans LE, Alhazzani W, et al.: Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017, 45:486-552. 10.1097/CCM.0000000000002255
2. Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016, 315:801-10. 10.1001/jama.2016.0287
3. Fleischmann C, Scherag A, Adhikari NK, et al.: Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016, 195:259-72. 10.1164/rccm.201504-0781OC
4. Holder AL, Gupta N, Lalai E, et al.: Predictors of early progression to severe sepsis or shock among emergency department patients with nonsevere sepsis. Int J Emerg Med. 2016, 9:10. 10.1186/s12245-016-0106-7
5. Sigma. Predictors of 30-day mortality in medical patients with severe sepsis or septic shock. 2014;9(2):47-52. www.sigmajournal.com. Accessed February 13. (2018). https://doi.org/10.1111/j.1746-1440.2014.04208.x
6. Chen K, Gao C, Zhou Q, Li W, Lin Z: Predictors of in-hospital mortality for sepsis patients in intensive care units. Int J Clin Exp Med. 2016, 9:4029-34.
7. Wang YJ, Chen YX, Guo SB, Mei X, Yang P: Predictive performance of quick sepsis-related organ failure assessment for mortality and ICU admission in patients with infection at the ED. Am J Emerg Med. 2016, 34:1788-95. 10.1016/j.ajem.2016.06.015
8. Houwink AP, Rijkenberg S, Bosman RJ, van der Voort PH: The association between lactate, mean arterial pressure, central versus oxygen saturation and peripheral temperature and mortality in severe sepsis: a retrospective cohort analysis. Crit Care. 2016, 20:56.
9. Shrestha P, Mohan A, Sharma S, et al.: To determine the predictors of mortality and morbidity of sepsis in medical ICU of All India Institute of Medical Sciences (AIIMS), New Delhi, India. Chest. 2012, 142:407. 10.1378/chest.1388695
10. Mohr NM, Vakkalanka JP, Fain BA, et al.: Serum anion gap predicts lactate poorly, but may be used to identify sepsis patients at risk for death: A cohort study. J Crit Care. 2018, 44:225-8. 10.1016/j.jcrc.2017.10.045
11. Spitalnic S, Sidman RD, Monti J: Serum bicarbonate and anion gap cannot reliably predict elevated serum lactate levels. Ann Emerg Med. 2004, 44:54. 10.1016/j.annemergmed.2004.07.176
12. Aronovich D, Trotter M, Rivera C, et al.: Is serum lactate necessary in patients with normal anion gap and serum bicarbonate?. West J Emerg Med. 2015, 16:564-6. 10.5811/westjem.2015.2.23906
13. Evans L, Rhodes A, Alhazzani W, et al.: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2015. Crit Care Med. 2015, 43:567-73. 10.1097/ccm.0000000000005337
14. Norisomi DT, Soriano FG, Kellum JA, Cappi SB, Biselli PJ, Libório AB, Park M: Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study. Crit Care Med. 2009, 37:2735-9. 10.1097/ccm.0b013e3181e59165
15. Gunnesson KJ, Saul M, He S, Kellum JA: Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Crit Care. 2006, 10:822. 10.1186/cc5387
16. Mikkelsen ME, Militzaides AN, Gaieski DF, et al.: Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009, 37:1670-7. 10.1097/01.ccm.0b013e318199c668
17. Casserly B, Phillips GJ, Schorr C, et al.: Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med. 2015, 43:567-73. 10.1097/CCM.0000000000001742
18. Broder G, Weil MH: Excess lactate: an index of reversibility of shock in human patients. Science. 1964, 145:1457-9. 10.1126/science.145.3615.1457
19. Khoosavani H, Shahpori R, Stelfox HT, Kirkpatrick AW, Laupland KB: Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill. Crit Care. 2009, 13:890. 10.1186/cc7918
20. Villar J, Short JH, Lighthall G: Lactate predicts both short- and long-term mortality in patients with and without sepsis. Infect Dis (Auckl). 2019, 12:1178633719862776. 10.1177/1178633719862776
21. Bellomo R, Kellum JA, Ronco C, et al.: Acute kidney injury in sepsis. Intensive Care Med. 2017, 43:816-28. 10.1007/s00134-017-4755-7
22. Barrantes F, Tian J, Vazquez R, Amoateng-Adjepong Y, Manthous CA: Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med. 2008, 36:1397-405. 10.1097/CCM.0b013e3181668be0
23. Oppert M, Engel C, Brunhorst FM, et al.: Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008, 23:904-9. 10.1093/ndt/gfm610
24. Mitra B, Roman C, Charters KE, O'Reilly G, Gantner D, Cameron PA: Lactate, bicarbonate and anion gap for evaluation of patients presenting with sepsis to the emergency department: a prospective cohort study. Emerg Med Australas. 2020, 32:20-4. 10.1111/1742-6723.13524
25. Mohr NM, Skow B, Wittrock A, et al.: Improving access to high quality sepsis care in a South Dakota emergency telemedicine network. Rural Telehealth Research Center, Grand Forks, North Dakota; 2017.
26. Shrestha GS, Kvizera A, Lundeg G, et al.: International Surviving Sepsis Campaign guidelines 2016: the perspective from low-income and middle-income countries. Lancet Infect Dis. 2017, 17:895-5. 10.1016/S1473-3099(17)30455-X
27. Cooper DJ, Walley KR, Wiggs BR, Russell JA: Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. 1990, 112:492-8. 10.7326/0003-4819-112-7-492
28. Mathieu D, Neviere R, Billard V, Fleyfel M, Wattel F: Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med. 1991, 19:1352-6. 10.1097/00003246-199111000-00008
29. Jaber S, Paugam C, Futier E, et al.: Sodium bicarbonate therapy for patients with severe metabolic acidemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018, 392:51-40. 10.1016/S0140-6736(18)31085-8
30. Zhang Z, Zhu C, Mo L, Hong Y: Effectiveness of sodium bicarbonate infusion on mortality in septic patients with metabolic acidosis. Intensive Care Med. 2018, 44:1888-95. 10.1007/s00134-018-5379-2